Tonix Pharmaceuticals Logo

  • About
    • Leadership
      • Executive Team
      • Board of Directors
      • Scientific Advisory Board
    • Facilities
  • Therapeutic Areas
    • Central Nervous System
      • Fibromyalgia
      • Posttraumatic Stress Disorder
      • Long Covid
      • Cocaine Intoxication
      • Migraine
      • Depression
    • Immunology
      • Organ Transplant Rejection
      • Gastro-Intestinal Cancers
    • Infectious Disease
      • COVID-19
      • Long COVID
      • Smallpox
    • Rare Disease
      • Prader-Willi Syndrome
  • Pipeline
    • Central Nervous System
      • TNX-102 SL
      • TNX-601 CR
      • TNX-1300
      • TNX-1900
    • Immunology
      • TNX-1500
      • TNX-1700
    • Infectious Disease
      • TNX-102 SL
      • TNX-1840/TNX-1850
      • TNX-3500
      • TNX-801
    • Rare Disease
      • TNX-2900
    • Scientific Presentations
    • Expanded Access Policy
  • Clinical Trials
  • News & Events
    • Tonix in the News
    • Press Releases
    • Investor Presentations
    • IR Events
    • Op-eds
  • Investors
    • News & Events
    • Presentations
    • Multimedia
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact Us

Tonix is enrolling participants in a Phase 3 trial for fibromyalgia, the RESILIENT study. For more information, please visit www.resilientstudy.com or www.clinicaltrials.gov (NCT05273749).

Multimedia

Investors

Investors

  • Overview
  • News & Events
    • Tonix in the News
    • Press Releases
    • IR Events
    • Email Alerts
    • Op-Eds
  • Presentations
  • Multimedia
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
Developing a PTSD Therapeutic - Phase 3 Clinical Development
Nov 12, 2020

Developing a PTSD Therapeutic - Phase 3 Clinical Development

Antibody vs. T Cell Immunity: Is a Single Vaccine Enough to Stop COVID-19
Sep 24, 2020

Antibody vs. T Cell Immunity: Is a Single Vaccine Enough to Stop COVID-19

Dr. Seth Lederman presents at the Proactive One2One Virtual Event on August 18, 2020
Aug 18, 2020

Dr. Seth Lederman presents at the Proactive One2One Virtual Event on August 18, 2020

Bringing new medicines to market despite subjective endpoints, Seth Lederman
Aug 11, 2020

Bringing new medicines to market despite subjective endpoints, Seth Lederman

Dr. Seth Lederman presents a vaccine tutorial covering the challenges and opportunities of developing a vaccine for COVID-19
Aug 11, 2020

Dr. Seth Lederman presents a vaccine tutorial covering the challenges and opportunities of developing a vaccine for COVID-19

Dr. Seth Lederman interviewed by Christine Corrado of Proactive Investors to discuss strategic partnerships in developing vaccines for COVID-19
Jul 17, 2020

Dr. Seth Lederman interviewed by Christine Corrado of Proactive Investors to discuss strategic partnerships in developing vaccines for COVID-19

Dr. Seth Lederman interviewed by Jane King on New to the Street to discuss Tonix’s portfolio of product candidates to fight COVID-19
Jul 8, 2020

Dr. Seth Lederman interviewed by Jane King on New to the Street to discuss Tonix’s portfolio of product candidates to fight COVID-19

Dr. Seth Lederman interviewed on Bloomberg TV to discuss the goals & timeline for development of TNX-1800, Tonix’s live replicating COVID-19 vaccine candidate.
Jul 8, 2020

Dr. Seth Lederman interviewed on Bloomberg TV to discuss the goals & timeline for development of TNX-1800, Tonix’s live replicating COVID-19 vaccine candidate.

Seth Lederman interviewed by KWTX’s Haley Vyrostek about Tonix’s partnership with Fujifilm Diosynth to manufacture and develop their COVID-19 vaccine candidate, TNX-1800, for clinical trial supply.
Jun 17, 2020

Seth Lederman interviewed by KWTX’s Haley Vyrostek about Tonix’s partnership with Fujifilm Diosynth to manufacture and develop their COVID-19 vaccine candidate, TNX-1800, for clinical trial supply.

Efforts to Manufacture a COVID-19 Vaccine (Podcast)
Jun 9, 2020

Efforts to Manufacture a COVID-19 Vaccine (Podcast)

rss_feed RSS
  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Next Pagearrow_forward
email icon Sign up for Email Alerts
twitter icon linkedin icon facebook icon
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Site Map

© 2022 Tonix Pharmaceuticals Holding Corp.